Total Payments
$20,487
2022 Payments
$120.83
Companies
9
Transactions
106
Medicare Patients
1,781
Medicare Billing
$299,004
Payment Breakdown by Category
Consulting$9,730 (47.5%)
Food & Beverage$4,899 (23.9%)
Research$4,360 (21.3%)
Travel$1,499 (7.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,730 | 4 | 47.5% |
| Food and Beverage | $4,899 | 59 | 23.9% |
| Unspecified | $4,360 | 39 | 21.3% |
| Travel and Lodging | $1,499 | 4 | 7.3% |
Payments by Type
General
$16,128
67 transactions
Research
$4,360
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $8,636 | 37 | $0 (2021) |
| Gilead Sciences, Inc. | $7,985 | 33 | $0 (2022) |
| GlaxoSmithKline, LLC. | $2,169 | 17 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $728.94 | 9 | $0 (2020) |
| Janssen Products, LP | $468.43 | 4 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $214.03 | 2 | $0 (2019) |
| EMD Serono, Inc. | $150.47 | 2 | $0 (2017) |
| AbbVie, Inc. | $117.30 | 1 | $0 (2018) |
| Janssen Biotech, Inc. | $17.74 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $120.83 | 1 | Gilead Sciences, Inc. ($120.83) |
| 2021 | $2,692 | 3 | Gilead Sciences, Inc. ($2,570) |
| 2020 | $554.92 | 7 | Merck Sharp & Dohme Corporation ($529.38) |
| 2019 | $2,855 | 34 | GlaxoSmithKline, LLC. ($991.80) |
| 2018 | $9,479 | 24 | ViiV Healthcare Company ($5,866) |
| 2017 | $4,786 | 37 | ViiV Healthcare Company ($2,030) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/06/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $120.83 | General |
| 07/15/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $3.39 | General |
| Category: HIV | ||||||
| 07/07/2021 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $118.92 | General |
| Category: HIV | ||||||
| 03/25/2021 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,570.00 | General |
| 07/01/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $12.12 | General |
| Category: HIV | ||||||
| 05/07/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: HIV | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $48.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $39.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $226.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $149.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $41.07 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $35.94 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $15.40 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $213.23 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $98.03 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $48.78 | Research |
| Study: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $39.01 | Research |
| Study: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $14.63 | Research |
| Study: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | ||||||
| 12/03/2019 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $116.57 | General |
| Category: HIV | ||||||
| 09/24/2019 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HIV | ||||||
| 09/20/2019 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $161.24 | Research |
| Study: A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH | ||||||
| 09/20/2019 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $161.24 | Research |
| Study: A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH | ||||||
| 09/18/2019 | Janssen Products, LP | Symtuza (Drug) | Food and Beverage | In-kind items and services | $116.07 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ViiV Healthcare Company | $1,215 | 8 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | GlaxoSmithKline, LLC. | $1,177 | 4 |
| A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH | GlaxoSmithKline, LLC. | $991.80 | 13 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $453.67 | 6 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ViiV Healthcare Company | $419.90 | 5 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 577 | 577 | $263,090 | $93,263 |
| 2021 | 5 | 1,032 | 1,032 | $432,187 | $191,622 |
| 2020 | 8 | 172 | 199 | $38,194 | $14,119 |
Total Patients
1,781
Total Services
1,808
Medicare Billing
$299,004
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | Office | 2022 | 180 | 180 | $235,800 | $87,331 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 217 | 217 | $27,245 | $5,887 | 21.6% |
| Q0247 | Injection, sotrovimab, 500 mg | Office | 2022 | 180 | 180 | $45.00 | $45.00 | 100.0% |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | Office | 2021 | 276 | 276 | $249,780 | $132,315 | 53.0% |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | Office | 2021 | 115 | 115 | $104,075 | $38,365 | 36.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 197 | 197 | $55,096 | $12,316 | 22.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 153 | 153 | $23,163 | $8,622 | 37.2% |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | Office | 2021 | 182 | 182 | $45.50 | $2.78 | 6.1% |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | Office | 2021 | 109 | 109 | $27.25 | $1.19 | 4.4% |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | Office | 2020 | 19 | 19 | $14,725 | $6,348 | 43.1% |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | Office | 2020 | 11 | 11 | $8,525 | $3,675 | 43.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 44 | 46 | $7,838 | $1,404 | 17.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 20 | 20 | $1,980 | $1,137 | 57.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 34 | $3,774 | $816.26 | 21.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 20 | 20 | $1,340 | $739.18 | 55.2% |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | Office | 2020 | 19 | 38 | $9.50 | $0.38 | 4.0% |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | Office | 2020 | 11 | 11 | $2.75 | $0.11 | 4.0% |
About Dr. Kenneth Lichtenstein, MD
Dr. Kenneth Lichtenstein, MD is a Infectious Disease healthcare provider based in Palm Springs, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740370428.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Lichtenstein, MD has received a total of $20,487 in payments from pharmaceutical and medical device companies, with $120.83 received in 2022. These payments were reported across 106 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($9,730).
As a Medicare-enrolled provider, Lichtenstein has provided services to 1,781 Medicare beneficiaries, totaling 1,808 services with total Medicare billing of $299,004. Data is available for 3 years (2020–2022), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Palm Springs, CA
- Active Since 10/13/2006
- Last Updated 02/29/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1740370428
Products in Payments
- MK-8591A (Drug) $529.38
- DOVATO (Drug) $399.95
- Symtuza (Drug) $353.21
- Biktarvy (Drug) $318.36
- PREZCOBIX (Drug) $225.51
- TRIUMEQ (Drug) $200.00
- SEROSTIM (Biological) $150.47
- ISENTRESS (Drug) $145.56
- JULUCA (Drug) $140.61
- RUKOBIA (Drug) $118.92
- Mavyret (Drug) $117.30
- Truvada (Drug) $116.34
- Epclusa (Drug) $106.95
- CABENUVA (Biological) $3.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Palm Springs
Dr. Shubha Kerkar, Md, MD
Infectious Disease — Payments: $23,166
Infectious Disease $23,166
Dr. Cyril Gaultier, Md, MD
Infectious Disease — Payments: $19,366
Infectious Disease $19,366
Phyllis Ritchie, Md, MD
Infectious Disease — Payments: $1,355
Infectious Disease $1,355
Christina Vu
Infectious Disease — Payments: $88.36
Infectious Disease $88.36
Dave Patel
Infectious Disease — Payments: $34.68
Infectious Disease $34.68